To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
The technical storage or access that is used exclusively for statistical purposes.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Dr. Pravin Dugel: Kodiak Sciences Announces Completion of Enrollment in the Company’s Phase 1 Safety and Tolerability Study in Patients with Retinal Disease
/ Uncategorized /by retinalconsultantsPALO ALTO, Calif., Aug. 31, 2018 /PRNewswire/ — Kodiak Sciences Inc., a clinical stage biopharmaceutical company specializing in novel therapeutics to treat high prevalence ophthalmic diseases, today announced that enrollment of patients in the company’s phase 1 safety and tolerability study has been completed. First patient in was dosed on July 12, 2018 and last patient […]
Dr. Pravin U. Dugel Treats First Patient with KSI-301
/ Uncategorized /by retinalconsultantsWe are pleased to share that the first patient in Kodiak’s phase I trial was treated by Dr. Pravin Dugel of the Retinal Consultants of Arizona. The injection was uneventful. Day 2 assessment was within normal limits with no signs of inflammation and with clear ocular media. Kodiak is A Phase I Open Label, Multi-center […]
Dr. Derek Kunimoto Discusses the CentraSight Implantable Telescope – AZTV Phoenix
/ Uncategorized /by retinalconsultantsDr. Derek Kunimoto visits the AZTV studios to discuss CentraSight’s Implantable Telescope for people with end-stage macular degeneration (wet and dry). For more information, call 602-222-2221 or visit www.CentraSight.com. Age-related macular degeneration (AMD) is the most common cause of severe vision loss in patients over 65. This condition involves a breakdown of the macula, the central […]
Ocular Surgery News: Treatment of DME poses complex choices, strives to overcome limitations
/ Uncategorized /by retinalconsultantsDr. Pravin U. Dugel – Ocular Surgery News U.S. Edition, June 25, 2018 Unmet needs and new options There are unmet needs for DME, mainly related to the high rate of poor responders and the burden of frequent injections. “There are still patients that have suboptimal improvement, so better efficacy is still an unmet need. […]
Healthy Vision Awareness!
/ Newsletters /by retinalconsultantsAccording to the American Academy of Ophthalmology, approximately 37 million adults in America have age-related macular degeneration, cataract, diabetic retinopathy, or glaucoma, all of which can cause visual impairment or blindness. However, recent studies show that making healthy choices and getting regular eye exams can help reduce a person’s risk of vision loss. In support […]
Dr. Pravin U. Dugel: Predictive Data From the HAWK and HARRIER Studies (Video)
/ Uncategorized /by retinalconsultantsPravin U. Dugel, MD, discusses the HAWK and HARRIER studies, particularly with regard to whether the disease activity assessment done at week 16 can predict which patients can be extended to 12 weeks. He also explains why this is important from a clinical standpoint. Interview from the 2018 ARVO Annual Meeting where leading experts recap […]
Retinal Consultants of Arizona is Now Hiring Ophthalmic Technicians to Travel with our Amazing Physicians and Staff!
/ Uncategorized /by retinalconsultantsThe ideal candidate will possess the following. Ophthalmology experience preferred, but willing to train the right candidate with Medical Assistant Experience. Medical Assistant must possess certification from an accredited program Must be able to work flexible hours and be able to travel via car or plane throughout the state. Photography (FA and OCT) experience helpful Must […]
Dr. Pravin U. Dugel – Modern Retina from Ophthalmology Times
/ Uncategorized /by retinalconsultantsThese novel strategies may change DME treatment paradigm By: Michelle Dalton, ELS; Reviewed by Pravin U. Dugel, MD There is no denying that the anti-vascular endothelial growth factor A (anti-VEGF-A) monotherapy has “absolutely revolutionized our treatment of diabetic macular edema (DME).” However, there is a subset of patients in whom the anti-VEGFs are not an […]
Dr. Pravin Dugel: Brolucizumab: A New Anti-VEGF Agent For Wet AMD
/ Uncategorized /by retinalconsultantsIn this interview from AAO 2017, Dr. Pravin Dugel outlines the results of two phase 3 trials of brolucizumab, a novel anti-VEGF agent for treating neovascular AMD. Brolucizumab is the smallest active unit of a human monoclonal antibody, which allows for concentrated molar dosing. The two trials, dubbed HAWK and HARRIER, suggest that extended dosing is viable. […]
Orbis International Welcomes New Members to its Board of Directors
/ Uncategorized /by retinalconsultantsOrbis welcomes Dr. Pravin Dugel, managing partner, Retinal Consultants of Arizona, and David Gitlin, President, UTC Aerospace Systems, to its Board of Directors. Pravin has been involved with Orbis since 2010 as a member of our Volunteer Faculty, specializing in retinal diseases including diabetic retinopathy. “I am extremely honored to join the Orbis Board of […]